IntrinsicIntrinsic
← All summaries

Clene Inc.

CLNN
Financials & Chart →

Business Summary

Clene Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN®) therapeutics. The company's core business model revolves around its proprietary electro-crystal-chemistry drug development platform, which produces nanocrystals of transition elements with unique catalytic activities. These therapeutics are designed to drive, support, and maintain beneficial metabolic and energetic cellular reactions in diseased cells. Clene generates an immaterial amount of revenue from license and supply agreements for dietary (mineral) supplements, but its primary focus and future revenue potential are tied to its drug candidates. The company's primary customer segments, once drugs are approved, would be patients suffering from neurodegenerative diseases, with a particular focus on central nervous system disorders. The company emphasizes its "first mover advantage" due to its proprietary manufacturing knowledge and the "wide range of applicability" of its CSN therapeutics, given that energy metabolism is fundamental to all living cells. The "flexibility and tunability" of its platform allows for the development of various single elemental and composite nanocrystals.

Clene's detailed product and service line breakdown includes its lead drug asset, CNM-Au8, a highly concentrated aqueous suspension of catalytically-active, clean-surfaced, faceted gold nanocrystals. CNM-Au8 is in development for Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's Disease (PD). Its mechanism of action targets mitochondrial dysfunction by catalyzing NAD+ production, alleviating oxidative stress, and reducing misfolded proteins. The company also has other therapeutic assets in early stages of development, including CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent comprised of zinc and silver ions in an aqueous solution, and CNM-AgZn17, a broad-based antiviral and antibacterial agent in a gel polymer formulation for topical application. Additionally, Clene develops dietary supplements, such as rMetx™ (ZnAg Immune Boost) sold through its subsidiary dOrbital, Inc., and KHC46 (Gold Factor™), an aqueous gold dietary supplement licensed exclusively to 4Life Research LLC.

For the fiscal year ended December 31, 2025, Clene reported a total revenue of $0 . The company incurred a loss from operations of $23.1 million and a net loss of $26.2 million . Basic and diluted EPS were not explicitly stated as separate figures but are implied by the net loss. Cash and cash equivalents stood at $5.2 million as of December 31, 2025, while total debt, including senior secured convertible promissory notes, was $15.0 million for the 2025 SSCP Notes and $12.0 million for the 2024 SSCP Notes. The accumulated deficit as of December 31, 2025, was $308.3 million .

Comparing year-over-year, the company's loss from operations decreased from $33.1 million in 2024 to $23.1 million in 2025. Similarly, the net loss decreased from $39.4 million in 2024 to $26.2 million in 2025. Research and development expenses decreased from $20.1 million in 2024 to $14.0 million in 2025. Net cash used in operating activities decreased from $21.3 million in 2024 to $18.5 million in 2025. Cash and cash equivalents declined from $12.2 million in 2024 to $5.2 million in 2025. The accumulated deficit increased from $282.1 million in 2024 to $308.3 million in 2025.

Significant operational developments during the period include continued support for multiple Expanded Access Programs (EAPs) for ALS, including EAP01, EAP02, and the ACT-EAP, the latter funded by a four-year NIH grant totaling $45.1 million , with subawards to Clene potentially reaching $30.9 million . The company announced new long-term CNM-Au8 treatment results for survival and NfL levels from the HEALEY ALS Platform Trial OLE in June 2024, showing approximately 60% decreased risk of death in CNM-Au8 30 mg treated patients compared to matched PRO-ACT controls . In August 2024, combined analyses from the HEALEY ALS Platform Trial and RESCUE-ALS trials showed CNM-Au8 NfL Responders demonstrated a 28% mean reduction in NfL levels compared to baseline . In December 2025, the company announced statistically significant decreases in NfL and GFAP levels in the ACT-EAP and HEALEY ALS Platform Trial, with NfL and GFAP biomarker decline associated with improved survival, showing an 80% reduction in the risk of death compared to Regimen A concurrent controls for participants with the greatest declines . In January 2026, exploratory findings identified IGFBP7 as an additional pharmacodynamic biomarker of treatment response to CNM-Au8 30 mg, with responders demonstrating 78% mortality risk reduction compared to concurrently randomized controls . For MS, the company commenced enrollment in the MS EAP in September 2024. In April 2025, further evidence of remyelination and neuronal repair from analyses of the VISIONARY-MS LTE identified consistent anatomical and physiologic effects within the same trial participants resulting in cognition and vision improvement.

Business Outlook

Clene Inc. plans to submit a New Drug Application (NDA) for CNM-Au8 for ALS under an accelerated approval pathway by the end of June 2026 . This submission is contingent on the outcome of a Type C in-person meeting with the FDA in the first quarter of 2026, where the company will discuss statistically significant reductions in NfL and GFAP and their association with longer survival, with meeting minutes expected early in the second quarter of 2026 . A planned Phase 3 RESTORE-ALS trial is slated to commence in the second half of 2026 , contingent on funding, and will serve as the post-approval confirmatory study.

A major growth area for Clene is the potential commercialization of CNM-Au8 for ALS. The company estimates the global ALS market value will be greater than $1.5 billion by 2032 . The planned NDA submission by June 2026 and subsequent Phase 3 RESTORE-ALS trial in the second half of 2026 are critical milestones. The RESTORE-ALS trial is designed to investigate improved survival as a primary endpoint and delayed time to ALS clinical worsening events as a secondary efficacy endpoint. The company has received a four-year NIH grant totaling $45.1 million to support the ACT-EAP for CNM-Au8 treatment of ALS, with subawards to Clene potentially totaling up to $30.9 million and extending to August 31, 2027 . This grant provides funding for ongoing clinical activities and is a significant financial support for the ALS program.

Another growth vector is the development of CNM-Au8 for Multiple Sclerosis (MS). The global MS market value is estimated to be approximately $23 billion . Clene met with the FDA in a Type B end of Phase 2 meeting during the third quarter of 2025 to discuss a planned Phase 3 study focusing on cognition improvement as an adjunct to standard-of-care MS therapies. The FDA expressed openness to considering cognition as a primary endpoint . The company plans to collaborate with regulatory health authorities from the FDA, European Medicines Agency (EMA), and other international bodies, as well as MS experts and patient representatives, to define the path for CNM-Au8 into Phase 3 and potential future approval.

Operationally, Clene intends to manufacture most, if not all, of any approved drugs itself. The company's North East, Maryland facility is GMP compliant and houses the specialized electro-crystal-chemistry devices for CSN therapeutic production. Current production capabilities are believed to be sufficient for research, development, and ongoing/planned clinical trials and EAPs, with processes scalable for early commercially viable quantities . Contingent upon successful future commercialization and funding, Clene plans to develop its 74,210 square foot Elkton, Maryland facility to materially increase manufacturing capacity post-commercialization . The company has implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts, reducing employee compensation, and eliminating certain staff positions .

For capital allocation, research and development expenses were $14.0 million for the year ended December 31, 2025. The company generated $10.6 million of gross proceeds from its equity distribution agreement and $1.5 million from the issuance of senior secured convertible promissory notes during the year ended December 31, 2025. Subsequent to December 31, 2025, Clene generated $6.0 million of gross proceeds from the issuance of Common Stock and warrants in a registered direct offering. The company's ability to continue as a going concern requires obtaining sufficient additional funding, which may include equity and debt financing, licensing or collaboration arrangements, and utilizing its existing at-the-market facility and potential proceeds from warrant and stock option exercises.

Structural headwinds and execution risks management explicitly flagged include the substantial dependence on the successful commercialization of drug candidates, the fact that the company currently does not generate revenue from commercial sales of drug candidates and may not become profitable, and the significant net losses and net operating cash outflows incurred since inception, which are expected to continue . The company's ability to continue as a going concern is contingent on obtaining sufficient funding, which may not be available on acceptable terms or at all, potentially forcing delays, limitations, reductions, or termination of drug development or commercialization efforts . Unstable market and economic conditions, including those from geo-political actions and inflation, may adversely affect financing strategies and increase costs . The company also faces the risk that its drug candidates, being metallic nanocrystal therapeutic candidates, are considered emerging and novel, with limited clinical trial data and regulatory precedent, leading to uncertainty regarding regulatory approval and commercial viability .

Risk Factors

Clene Inc. faces several material risks, including its substantial dependence on the successful commercialization of drug candidates, which may fail to materialize or experience significant delays, and the fact that it currently generates no revenue from commercial drug sales and may not achieve profitability. The company has incurred significant net losses and net operating cash outflows, with an accumulated deficit of $308.3 million as of December 31, 2025, and requires additional funding to continue as a going concern, which may not be available on acceptable terms or at all, potentially forcing delays or termination of drug development. Unstable market and economic conditions, including geo-political actions and inflation, could adversely affect financing and increase costs. The company's limited operating history and the emerging nature of metallic nanocrystal therapeutics, with uncertain mechanisms of action and limited regulatory precedent, pose significant risks to clinical trial design, outcomes, and regulatory approval. There is also a risk that drug candidates may accumulate in the body, with long-term effects being uncertain, and the company has not completed reproductive or carcinogenicity studies, which are required. Furthermore, the company has identified material weaknesses in its internal control over financial reporting related to an ineffective control environment, preparation and review of account reconciliations, segregation of duties over manual journal entries, and IT general controls, which could lead to material misstatements in financial reporting. The company manufactures all its drug candidates internally, and delays or damage to its manufacturing facilities, or difficulties in scaling up production, could negatively affect its business. Competition from other pharmaceutical and biotechnology companies with greater resources is substantial, and the company's intellectual property protection, while extensive with over 160 issued patents worldwide , is subject to challenges, invalidation, and the limitations of patent life, potentially allowing competitors to commercialize similar products.

Management Priorities

Management's message to shareholders emphasizes an innovation-focused and scientifically-driven approach to drug development, leveraging their proprietary electro-crystal-chemistry platform to create novel clean-surfaced nanotechnology (CSN®) therapeutics. They highlight their "first mover advantage" in manufacturing and understanding these nanocrystals, as well as the "wide range of applicability" and "flexibility and tunability" of their platform for various disease states. A key strategic priority is the advancement of CNM-Au8, particularly for ALS, with a plan to submit an NDA under an accelerated approval pathway by the end of June 2026 , contingent on funding, and to commence a Phase 3 RESTORE-ALS trial in the second half of 2026 as a post-approval confirmatory study. Management also stresses the robust safety profile of CNM-Au8, with over 1,100 participant-years of exposure and no significant safety concerns identified . Another strategic priority is the continued development of CNM-Au8 for Multiple Sclerosis, with plans to work with regulatory authorities to advance into Phase 3 focusing on cognition improvement. The company's ability to continue as a going concern is explicitly tied to obtaining additional funding, and they are actively exploring equity and debt financing, licensing, and utilizing existing facilities.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Our Clinical Pipeline, Other Therapeutic Assets, Dietary Supplements
  3. [3] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  4. [4] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  5. [5] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  6. [6] Item 8, Consolidated Balance Sheets
  7. [7] Item 8, Note 8 — Debt
  8. [8] Item 8, Note 8 — Debt
  9. [9] Item 8, Consolidated Balance Sheets
  10. [10] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  11. [11] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  12. [12] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  13. [13] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  14. [14] Item 8, Consolidated Statements of Cash Flows
  15. [15] Item 8, Consolidated Statements of Cash Flows
  16. [16] Item 8, Consolidated Balance Sheets
  17. [17] Item 8, Consolidated Balance Sheets
  18. [18] Item 1, Business — Financial Grants
  19. [19] Item 1, Business — Financial Grants
  20. [20] Item 1, Business — HEALEY ALS Platform Trial and Open Label Extension
  21. [21] Item 1, Business — HEALEY ALS Platform Trial and Open Label Extension
  22. [22] Item 1, Business — HEALEY ALS Platform Trial and Open Label Extension
  23. [23] Item 1, Business — HEALEY ALS Platform Trial and Open Label Extension
  24. [24] Item 1, Business — VISIONARY-MS—Long-Term Extension
  25. [25] Item 1, Business — Regulatory Pathway and Phase 3
  26. [26] Item 1, Business — Regulatory Pathway and Phase 3
  27. [27] Item 1, Business — Regulatory Pathway and Phase 3
  28. [28] Item 1, Business — ALS Market Opportunity
  29. [29] Item 1, Business — Financial Grants
  30. [30] Item 1, Business — MS Market Opportunity
  31. [31] Item 1, Business — Clinical Development of CNM-Au8 as a Disease-Modifying Therapeutic for MS
  32. [32] Item 1, Business — Manufacturing
  33. [33] Item 1, Business — Manufacturing
  34. [34] Item 1A, Risk Factors — Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our drug development or commercialization efforts.
  35. [35] Item 1A, Risk Factors — Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our drug development or commercialization efforts.
  36. [36] Item 1A, Risk Factors — Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our drug development or commercialization efforts.
  37. [37] Item 1A, Risk Factors — Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our drug development or commercialization efforts.
  38. [38] Item 1A, Risk Factors — Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our drug development or commercialization efforts.
  39. [39] Item 1A, Risk Factors — We have incurred significant net losses and net operating cash outflows since our inception and expect to continue to incur significant net losses for the foreseeable future.
  40. [40] Item 1A, Risk Factors — Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our drug development or commercialization efforts.
  41. [41] Item 1A, Risk Factors — Unstable market and economic conditions may have serious adverse consequences on our business, financial condition, results of operations, and prospects.
  42. [42] Item 1A, Risk Factors — There is significant uncertainty associated with our drug candidates and their viability as a commercial product.
  43. [43] Item 1, Business — Intellectual Property
  44. [44] Item 1, Business — Safety and Tolerability of CNM-Au8

Analysis on 5/20/2026